NCT03008343View on ClinicalTrials.gov

Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

December 1, 2017

Study Completion Date

July 1, 2019

Conditions
Recurrent Liver Carcinoma
Interventions
DEVICE

Irreversible Electroporation

One kind of electric ablation machine from Angiodynamic company (USA)

BIOLOGICAL

Natural killer

Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.

Trial Locations (1)

510665

Fuda cancer institute of Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Shenzhen Hank Bioengineering Institute

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT03008343 - Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer | Biotech Hunter | Biotech Hunter